Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Oct 04, 2023 4:03pm
86 Views
Post# 35669726

RE:RE:RE:RE:RE:RE:RE:I sure like this Jon

RE:RE:RE:RE:RE:RE:RE:I sure like this Jon
It's not a matter of accepting that xB3 doesn't work, zwerp. It's a matter of proving it. You have the lamentable characteristic of believing things that are unproven and touting them as facts. You have no proof that xB3 doesn't work. It's just you believing your own blah blah blah.
 
I like to stick with the facts. So far, the facts support management failures rather than technology failures. If the management wants to argue against their own failures then they'll have to point to the technology. They have always claimed, and still claim, that xB3 has not failed in any way, that there are no known problems with it.
 
They're in a trap. They won't admit they failed and they insist that xB3 works. Even if xB3 has secret problems, if they eventually admit to that then they are admitting they have been lying about xB3. They won't admit they've been lying and they won't admit they're failures - trapped.
 
But then along comes Midatech, LT and The Placee. Why did they want xB3? And why would they have taken Rathjen and Saltarelli? If they wanted xB3 for a pump and dump then they needed Rathjen to do the deal and to then stick around so that it would look like they all believed in xB3, even if xB3 didn't work.
 
Or the gang wanted xB3 because it did work. They could acquire xB3 for far less money if it didn't look like xB3 was worth much. So what do they do to fix that? It looks like they shelved xB3, brought in a market deflection with Cresence, cut the xB3 promotion everywhere, including by cutting the Corporate Presentation from 55 pages to 17 pages and leaving it mostly about Cresence. They touted the LT deal as the only hope for shareholders and then waited to take xB3 private by announcing that Biodexa will exit the drug delivery business. 
 
There is no evidence of xB3 failure. It appears, rather, that management either failed because of incompetence or the failure was set up by Rathjen so that she could take xB3 private in a situation she could be part of. 
 
About me being a part of Bioasis for 15 years, I learned about Bioasis in 2011 and was contracted to Bioasis from 2014 to 2021 - 7 years. I was paid to do it and I invested in the stock. Was that an obsession or a business decision? 
 
Of course, now, I would very much like Bioasis and Rathjen to be investigated by regulators. I don’t think it would go far, not with incompetence being on the table. And even if her purpose was to put xB3 and herself into private hands, she did telegraph everything she was going to do, even going so far as to put that little line in the documents stating that Biodexa/Midatech would not stay in the drug delivery business, and yet having Midatech tout the drugs they could make with xB3. To me, that meant that Midatech, LT, The Placee, Rathjen and Saltarelli all believed that xB3 worked and that Biodexa would sell it to them after the acquisition. Pretty slick. All legal and completely immoral, maybe illegal, if she purposefully destroyed the perceived value of xB3 with promotional ploys.
 
I understand your story, zwerp. You want to create maximum effect with little posts containing bombastic statements that you can’t be bothered to verify. We see that type of posting all over the internet, mostly from right wing Trumpsters. They all, and you, just wanna fight. The truth doesn’t matter in the least.
 
Fortunately, you all talk the same way, out of your astronomical yappers. You’re easily recognized because you never back up what you say with any citations, no proof whatsoever. We all know you’re too lazy to do the work, but you do serve an excellent purpose. You encourage the real story to be told.

TL;DR - who cares...
 
jd
<< Previous
Bullboard Posts
Next >>